Drug may prevent development of invasive bladder cancer, researchers say

A drug already approved for use in humans may prevent invasive bladder cancer, according to a study by researchers at the Stanford University School of Medicine. The drug, FK506, is commonly used to suppress the immune system in organ transplant recipients to combat rejection. The researchers found that low doses of FK506, also known as tacrolimus, prevented the development of invasive bladder cancer in 110 out of 10 laboratory mice that were given a carcinogen over five months. Read more here.